Business
CTT Pharmaceutical Holdings, Inc., (CTTH) Announces U.S. Patent for Therapeutic Composition for Treating Psoriasis with Cannabidiol and Corticosteroids
CTT Pharmaceutical Holdings, Inc., (CTTH) Announces U.S. Patent for Therapeutic Composition for Treating Psoriasis with Cannabidiol and Corticosteroids.
About this update from Ctt Pharmaceutical Holdings, Inc.
[{"type":"text","content":"\n\n HAMILTON, Ontario, Jan. 10, 2018 (GLOBE NEWSWIRE) -- CTT Pharmaceutical Holdings, Inc., (OTC:CTTH), an innovative life sciences company with an extensive portfolio of IP in novel drug delivery systems designed to improve patient outcomes and experiences, is pleased to announce that the US Patent and Trademark Office has granted the Company U.S. Patent # 9,833,461, titled, “Therapeutic Composition Comprising Cannabidiol and Corticosteroids”, under the classifications of “Chewable Tablets and Wafers”.  This newly-issued patent expands the Company’s patent portfolio to 4 issued (2 Canadian and 2 U.S.) with 2 patents pending and a Worldwide PCT.\n It has now been found that a combination of tetrahydrocannabinoid (THC) compound, a second cannabinoid and a steroid are useful to treat psoriasis and related conditions. The global psoriasis market size was valued at US$ 11.5 billion in 2016 and is estimated to grow at a CAGR of 9.3%. “We are in a unique position to leverage and monetize our technology as a result of the granted U.S., Canadian and Worldwide patents that make up our IP assets. Very few of the companies in the Oral Thin Film industry, to our knowledge, have any patents issued in regards to wafers and/or strips and as a result may be infringing on our patents,” said Dr. Pankaj Modi, CEO of CTTH. “The fastest growing product segment in the medical cannabis industry today are the cannabis oils and all the derivative products that utilize the cannabis oils; we believe our sub-lingual wafer, the CannaWafe, would be the most elegant and efficient product in this category.”   Through its wholly-owned Canadian subsidiary CTT Pharmaceuticals, Inc., the Company is currently in discussions with potential licensing and joint-venture partner opportunities from companies that are Licensed Producers (LP’s) in Canada, as well as Licensed Growers in the United States that offer medical and recreational cannabis products in California, Nevada, Colorado, Oregon, Washington, Alaska, Maine and Massachusetts. The Company expects to formalize and announce these arrangements in the first quarter of 2018. Hemp-derived cannabidiol (CBD) which can be delivered by the Company’s sub‑lingual wafer is expected to be a billion dollar market in just three years acco...